Immunovant, Inc.

US$30.53As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:IMVTHealthcare
Country USA
PE (Fwd) •••
TSR 7Y CAGR 16.70%
Div yield —
ROE (80.10%)
Biotechnology
Beta (5Y) 0.94
PE TTM —
TSR TTM 23.70%
Mkt cap US$6.306B
ROIC (52.64%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$39
28.56%
55.67%
Buy 0|9|1|7|2
3Q26
4Q26
1Q27
2Q27
Earnings per share$
0.69
0.72
0.69
0.76
21.07%
27.41%
18.99%
19.56%
Revenue$M
315.1
310.2
313.7
327.0
16.38%
8.47%
6.92%
9.87%
Peers (US$6.306B)
Cap (US$)
PE
6.210B
—
6.330B
124.2x
Capital
TTM
5Y
10Y
Leveragex
1.032
0.208
0.166
EBIT/Intx
1.327
0.369
0.273
Own earn%
(22.87)
96.74
111.78
Sh yield%
52.23
28.97
29.02
Owners
Insiders/Inst%
6.22
32.35
Short interest%
1.18
SBC / revenue%
0.78
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
16
Op margin range%
1–5
$1 testx
0.0
Incr. ROIC%
6